Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670578 | 1.00 | MAOB (0.35) | MAOBMAOAABL1EPHX2PIM1 | |
| SCHEMBL29664110 | 0.81 | ALDH1A1 (0.43) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL20670508 | 0.81 | ALDH1A1 (0.43) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL28042104 | 0.78 | ALOX5AP (0.39) | PIM1NPC1RAB9AKDM4EMAPT | |
| SCHEMBL30557826 | 0.77 | MAOB (0.54) | MAOBMAOAABL1EPHX2PIM1 | |
| SCHEMBL29786514 | 0.77 | ABL1 (0.46) | MAOBMAOAABL1EPHX2PIM1 | |
| SCHEMBL17766955 | 0.77 | MAOB (0.54) | MAOBMAOAABL1EPHX2PIM1 | |
| SCHEMBL17480164 | 0.77 | ABL1 (0.46) | MAOBMAOAABL1EPHX2PIM1 | |
| SCHEMBL30951611 | 0.75 | PIM1 (0.43) | ABL1EPHX2PIM1NPC1RAB9A | |
| SCHEMBL13043978 | 0.75 | PIM1 (0.43) | ABL1EPHX2PIM1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4141001-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2024-10-17 | — | — | US | disclosed |
| CN-110914262-B | Kappa opioid receptor antagonists and products and methods relating thereto | 斯克里普斯研究所 | 2024-04-05 | — | — | CN | disclosed |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4141001-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | MAOB 1634/4885MAOA 1402/4885ABL1 2584/4885 |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | MAOB 1608/4885MAOA 1368/4885ABL1 2613/4885 |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | MAOB 1592/4885MAOA 1367/4885ABL1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.